{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0072677\nAge: 67\nGender: Male\nSample ID: P-0072677-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Lung Adenocarcinoma\nSample Type: Primary\nTumor Purity: 20.0%\n=============\nDNA Variants:\nARID1A c.376G>A (p.G126S) - in 5.00% of 436 reads\nASXL1 c.1259C>T (p.A420V) - in 8.00% of 462 reads\nEGFR c.2156G>C (p.G719A) - in 7.00% of 313 reads\nEGFR c.2303G>T (p.S768I) - in 11.00% of 372 reads\nELF3 c.822C>G (p.H274Q) - in 12.00% of 504 reads\nEZH1 c.1951G>A (p.E651K) - in 13.00% of 289 reads\nMAP3K1 c.3632A>G (p.E1211G) - in 8.00% of 345 reads\nTP53 c.818G>T (p.R273L) - in 6.00% of 400 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with EGFR exon 20 insertion mutation\",\n    \"Drug Name\": \"Mobocertinib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed on or after platinum-based chemotherapy\",\n    \"Genomic Features\": \"EGFR exon 20 insertion mutation (c.2303G>T, p.S768I)\",\n    \"FDA-approval status\": \"Accelerated approval for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf\"\n  }\n}"
}